Advanced search×

Continuous vs. intermittent androgen deprivation therapy for metastatic prostate cancer.

Johan F Langenhuijsen, Dirk Badhauser, Berthold Schaaf, Lambertus A L M Kiemeney, J Alfred Witjes, and Peter F A Mulders

Urol Oncol (2011) PMID 21561791

OBJECTIVES: To analyze the predictive value of PSA for progression and the role of testosterone for quality of life (QOL) in patients with androgen deprivation therapy (ADT) for metastatic prostate cancer. MATERIALS AND METHODS: PSA and testosterone data were used from a phase III trial randomizing patients without progression and PSA < 4 ng/ml (n = 193), after 6 months induction course, between continuous (CAD) (n = 96) and intermittent (IAD) (n = 97) ADT. The 2-year risk of progression was calculated for baseline PSA, 'fast' and 'slow' PSA decline to < 4 ng/ml (60 days cut-off), PSA nadir, performance status and pain. Testosterone kinetics and QOL were also evaluated. Univariate Kaplan Meier survival analysis and log rank tests were used to compare the risk of progression. RESULTS: For progression analysis, 173 patients' data were available. The 2-year risk of progression for baseline PSA < 50 ng/ml, 50 to 0.2 to 4 ng/ml in CAD was 31% and 70% (P < 0.001), respectively. In the IAD group, a similar trend was seen. Patients with PSA nadir ≤ 0.2 ng/ml, though had significantly higher 2-year risk of progression compared to CAD (53% vs. 31% (P = 0.03), respectively. PSA decline showed no predictive value. Patients without pain had a significantly lower 2-year risk of progression in both groups. Without ADT testosterone remained at castrate level for 4 months. After the first and second IAD cycle 92% and 46%, respectively, had a normalized testosterone. No QOL difference was found, although more side effects occurred in CAD. CONCLUSIONS: Metastatic prostate cancer patients with high baseline PSA, pain, and high PSA nadir have a poor prognosis with ADT. Patients with low PSA nadir do significantly worse with IAD compared with CAD. Low testosterone after ADT and incomplete testosterone recovery may explain similar QOL. Therefore, IAD is not a good treatment option for many metastatic prostate cancer patients. Copyright © 2011 Elsevier Inc. All rights reserved.

DOI: 10.1016/j.urolonc.2011.03.008
Version: za2963e q8zac q8zb2 q8zc8 q8zdf q8zed q8zfc q8zg9

Similar articles you may find interesting…

  1. Should we follow-up serum testosterone in patients with advanced prostate cancer?
    Perachino M

    Expert Rev Anti Infect Ther 10(7):1031-5 (2010) PMID 20645692

    These results need to be confirmed by further prospective studies. Given this concept, lowering testosterone as much as possible should be the goal of androgen-deprivation therapy in patients with metastatic prostate cancer, as this may have an impact on patient survival....
  2. Blockade of testicular and adrenal androgens in prostate cancer treatment.
    Fernand F Labrie

    Nat Rev Urol 8(2):73-85 (2011) PMID 21243019

    Prostate cancer is the most hormone sensitive of all cancers. However, any hormonal therapeutic strategy must take into account the fact that two almost equivalent sources of androgens act in the prostate, namely testosterone of testicular origin, and the locally produced androgens t...
  3. Modeling prostate cancer in mice: limitations and opportunities.
    Patrick J PJ Hensley and Natasha N Kyprianou

    J Androl 33(2):133-44 (2012) PMID 21680808

    The complex dynamics of the tumor microenvironment and prostate cancer heterogeneity have confounded efforts to establish suitable preclinical mouse models to represent human cancer progression from early proliferative phenotypes to aggressive, androgen-independent and invasive metas...